Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

395 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-01

Study Completion Date

2022-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission

NCT01965340

Burn

COMPLETED NA

Neurotoxicity Evaluation of Beta-lactams in Intensive Care Unit and Identification of the Risk Factors

NCT03628300

Neurotoxicity Sepsis Beta Lactams +3 more

COMPLETED

The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients

NCT02446392

Sepsis

COMPLETED

Procalcitonin-Guided Antimicrobial Discontinuation

NCT00250666

Sepsis

COMPLETED PHASE4

DetermInants of Antimicrobial Use aNd De-escalAtion in Critical Care (DIANA)

NCT02920463

Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacteremia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bern ICU

Blood Culture

Intervention Type DIAGNOSTIC_TEST

Blood Culture

Lausanne ICU

Blood Culture

Intervention Type DIAGNOSTIC_TEST

Blood Culture

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Culture

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:

1. was treated at the ICU/IMC at the time of blood culture collection;
2. or has been admitted to ICU/IMC in the 48 hours after blood culture collection

Exclusion Criteria

1. Patient has a single positive blood culture with a common contaminant organism:

* coagulase negative staphylococci;
* Bacillus spp.;
* Corynebacterium spp.;
* Propionibacterium spp.;
* Aerococcus spp.;
* Micrococcus spp.
2. Explicit documentation that the patient does not want to participate in any study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No